Review: Immune cells and mediators of inflammatory arthritis

References

• Schett G, Kiechl S, Weger S, Mayr A, Oberhollenzer S, et al. High-sensitivity C-reactive protein and risk of non-traumatic fractures in the Bruneck Study. Arch Intern Med 2006; 166: 2495–2501
   PubMedGoogle Scholar
• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356–361
   PubMed Web of Science ®Google Scholar
• van der Helm-van Mil AH, Wesoly JZ, Huizinga TW. Understanding the genetic contribution to rheumatoid arthritis. Curr Opin Rheumatol 2005; 17: 299–304
   PubMed Web of Science ®Google Scholar
• Klareskog L, Padyukov L, Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 2007; 19: 49–54
   PubMed Web of Science ®Google Scholar
• Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 122–132
   PubMed Web of Science ®Google Scholar
• Pincus T. Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41: 1037–1041
   PubMed Web of Science ®Google Scholar
• Welsing PM, van Gestel AM, Swinkels HL, Kiemeney LA, van Riel PL. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001; 44: 2009–2017
   PubMed Web of Science ®Google Scholar
• Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum 2006; 54: 2784–2792
   PubMed Web of Science ®Google Scholar
• McInnes I, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Immunol 2007; 7: 429–442
   Google Scholar
• Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. Am J Pathol 1998; 152: 943–951
   PubMed Web of Science ®Google Scholar
• Weichselbaum A. Die feineren Veränderungen des Gelenkknorpels bei fungöser Synovitis und Karies der Gelenkenden. Archiv Pathol Anat Physiol Klin Med 1878; 73: 461–475
   Google Scholar
• Bromley M, Woolley DE. Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum 1984; 27: 968–975
   PubMed Web of Science ®Google Scholar
• Schett G, Stolina M, Bolon B, Middleton S, Adlam M, Brown H, Zhu L, Feige U, Zack DJ. Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum 2005; 52: 3192–3201
   PubMed Web of Science ®Google Scholar
• Hayer S, Redlich K, Korb A, Hermann S, Smolen J, Schett G. Tenosynovitis and osteoclast formation as the initial preclinical changes in a murine model of inflammatory arthritis. Arthritis Rheum 2006; 56: 79–88
   Google Scholar
• Van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34: 74–78
   PubMedGoogle Scholar
• Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, Uffmann M, Smolen JS. Very recent onset rheumatoid arthritis: Clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007; 46: 342–349
   PubMed Web of Science ®Google Scholar
• Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 2002; 110: 1419–1427
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL, et al. Bone resorption by osteoclasts. Science 2000; 289: 1504–1508
   PubMed Web of Science ®Google Scholar
• Li P, Schwarz EM, O'Keefe MaL, Boyce BF, Xing L. RANK signaling is not required for TNF-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 2004; 19: 207–213
   PubMed Web of Science ®Google Scholar
• Seitz M, Loetscher P, Fey MF, Tobler A. Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol 1994; 33: 613–619
   PubMedGoogle Scholar
• Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2523–2530
   PubMed Web of Science ®Google Scholar
• Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43: 250–258
   PubMed Web of Science ®Google Scholar
• Yoshida H, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990; 345: 442–444
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165–176
   PubMed Web of Science ®Google Scholar
• Dougall WC, Glaccum M, Charrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13: 2412–2424
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309–319
   PubMed Web of Science ®Google Scholar
• Pettit AR, Ji H, von Stechow D, Müller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001; 159: 1689–1699
   PubMed Web of Science ®Google Scholar
• Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304–309
   PubMed Web of Science ®Google Scholar
• Redlich K, Hayer S, Maier A, Dunstan CR, Tohidast AM, Lang S, et al. Tumor necrosis factor a—mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 2002; 46: 785–792
   PubMed Web of Science ®Google Scholar
• Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkB ligand and tumor necrosis factor—a in bone destruction in rheumatoid arthritis. Bone 2002; 30: 340–346
   PubMed Web of Science ®Google Scholar
• Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003; 170: 2655–2662
   PubMed Web of Science ®Google Scholar
• Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13: 156–163
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–1593
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000; 343: 1594–1602
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized placebo-controlled 52-week trial. Arthritis Rheum 2004; 50: 1400–1411
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111: 821–831
   PubMed Web of Science ®Google Scholar
• Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481–1488
   PubMed Web of Science ®Google Scholar
• Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J 1991; 10: 4025–4031
   PubMed Web of Science ®Google Scholar
• Zwerina J, Tzima S, Hayer S, Redlich K, Hoffmann O, Hanslik-Schnabel B, Smolen JS, Kollias G, Schett G. Heme oxygenase 1 (HO-1) regulates osteoclastogenesis and bone resorption. FASEB J. 2005; 19: 2011–2013
   Google Scholar
• Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115: 282–290
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T, CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54: 2817–2829
   PubMed Web of Science ®Google Scholar
• Wong PK, et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum 2006; 54: 158–168
   PubMed Web of Science ®Google Scholar
• Takayanagi H, et al. HT-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-gamma. Nature 2000; 408: 600–605
   PubMed Web of Science ®Google Scholar
• Udagawa N, et al. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation. J Exp Med 1997; 185: 1005–1012
   PubMed Web of Science ®Google Scholar
• Sato K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673–2682
   PubMed Web of Science ®Google Scholar
• McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821–831
   PubMed Web of Science ®Google Scholar
• Conaghan PG, Sloan VS, Papanstasiou P, Ortmann CE, O'Connor PJ, Grainger AJ, Emery P. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 2004; 50: 265–276
   Google Scholar